Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14)

被引：0

作者：

Reece, Donna E. ^{[1
]}

Rodriguez, Giovanni Piza ^{[1
]}

Belch, Andrew ^{[2
]}

Szwajcer, David ^{[3
]}

Pantoja, Mariela ^{[1
]}

Kovacs, Michael ^{[4
]}

Shustik, Chaim ^{[5
]}

Bahlis, Nizar J. ^{[6
]}

White, Darrell J. ^{[7
]}

Chen, Christine ^{[1
]}

Kukreti, Vishal ^{[1
]}

Anglin, Peter ^{[1
]}

Stewart, A. Keith ^{[8
]}

Trudel, Suzanne ^{[1
]}

机构：

[1] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada

[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[3] CancerCare Manitoba, Hematol, Winnipeg, MB, Canada

[4] London Hlth Sci Ctr, London, ON, Canada

[5] Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada

[6] Univ Calgary, Dept Hematol, Calgary, AB, Canada

[7] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada

[8] Mayo Clin Scottsdale, Scottsdale, AZ USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1485 / 1486

页数：2

共 50 条

[31] The Choice Of Regimens Based On Bortezomib For Patients With Newly Diagnosed Multiple Myeloma
Yang, Li
He, Jingsong
Han, Xiaoyan
Zheng, Gaofeng
Zheng, Weiyan
Wei, Guoqing
Wu, Wenjun
Ye, Xiujin
Shi, Jimin
Xie, Wanzhuo
Li, Li
Zhang, Jie
Huang, Weijia
Zhao, Yi
Huang, He
Zhang, Xuejin
Fu, Jiaping
Cai, Zhen
BLOOD, 2013, 122 (21)
[32] The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
He, Jingsong
Yang, Li
Han, Xiaoyan
Zheng, Gaofeng
Zheng, Weiyan
Wei, Guoqing
Wu, Wenjun
Ye, Xiujin
Shi, Jimin
Xie, Wanzhuo
Li, Li
Zhang, Jie
Huang, Weijia
Zhao, Yi
Huang, He
Zhang, Xuejin
Fu, Jiaping
Cai, Zhen
PLOS ONE, 2014, 9 (06):
[33] Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
Cavo, Michele
Bringhen, Sara
Testoni, Nicoletta
Omede, Paola
Marzocchi, Giulia
Ruggeri, Marina
Durante, Sandra
Di Raimondo, Francesco
Rossi, Davide
Gorgone, Ausilia
Patriarca, Francesca
Petrucci, Maria Teresa
Buttignol, Silvia
Levi, Anna
Offidani, Massimo
Nozzoli, Chiara
Ria, Roberto
Olivero, Barbara
Galli, Monica
Montefusco, Vittorio
Callea, Vincenzo
Falcone, Antonietta
De Vivo, Antonio
Boccadoro, Mafio
Terragna, Carolina
Palumbo, Antonio
BLOOD, 2009, 114 (22) : 741 - 741
[34] SUCCESSFUL STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER PRETREATMENT CONSISTING OF BENDAMUSTINE, PREDNISONE AND BORTEZOMIB IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Poenisch, W.
Ploetze, M.
Holzvogt, B.
Andrea, M.
Schliwa, T.
Heyn, S.
Franke, G. N.
Jentzsch, M.
Leiblein, S.
Schwind, S.
Lange, T.
Vucinic, V.
Al-Ali, H. K.
Niederwieser, D.
HAEMATOLOGICA, 2015, 100 : 604 - 604
[35] Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma
King, Justin
Fiala, Mark A.
Goldsmith, Scott R.
Stockerl-Goldstein, Keith E.
Schroeder, Mark A.
Ghobadi, Armin
Vij, Ravi
Wildes, Tanya M.
BLOOD, 2019, 134
[36] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Richardson, Paul G.
Weller, Edie
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raje, Noopur S.
Avigan, David E.
Xie, Wanling
Ghobrial, Irene M.
Schlossman, Robert L.
Mazumder, Amitabha
Munshi, Nikhil C.
Vesole, David H.
Joyce, Robin
Kaufman, Jonathan L.
Doss, Deborah
Warren, Diane L.
Lunde, Laura E.
Kaster, Sarah
DeLaney, Carol
Hideshima, Teru
Mitsiades, Constantine S.
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth C.
BLOOD, 2010, 116 (05) : 679 - 686
[37] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)
Roussel, Murielle
Moreau, Philippe
Hebraud, Benjamin
Laribi, Kamel
Jaccard, Arnaud
Dib, Mamoun
Slama, Borhane
Dorvaux, Veronique
Royer, Bruno
Frenzel, Laurent
Zweegman, Sonja
Klein, Saskia K.
Broijl, Annemiek
Jie, Kon-Siong
Wang, Jianping
Vanquickelberghe, Veronique
Boer, Carla de
Kampfenkel, Tobias
Gries, Katharine S.
Fastenau, John
Sonneveld, Pieter
LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883
[38] Bortezomib-Based Induction Therapy Followed by High-Dose Chemotherapy and Autologous Stem Cell transplantation in Newly-Diagnosed Myeloma: Initial Report From a Chinese Multiple-Center Study
Hu, Jiong
Shen, Zhi-Xiang
BLOOD, 2012, 120 (21)
[39] Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
Jackson, Graham
Galinsky, Jayne
Alderson, David E. C.
D'Souza, Vijay K.
Buchanan, Vanessa
Dhanasiri, Sujith
Walker, Simon
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (04) : 393 - 401
[40] Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
Mai, Elias K.
Hielscher, Thomas
Bertsch, Uta
Schlenzka, Jana
Salwender, Hans J.
Munder, Markus
Gerecke, Christian
Duehrsen, Ulrich
Brossart, Peter
Neben, Kai
Hillengass, Jens
Raab, Marc S.
Merz, Maximilian
Baertsch, Marc-Andrea
Jauch, Anna
Hose, Dirk
Martin, Hans
Lindemann, Hans-Walter
Blau, Igor W.
Scheid, Christof
Weisel, Katja C.
Goldschmidt, Hartmut
LEUKEMIA, 2019, 33 (01) : 258 - 261

← 1 2 3 4 5 →